Laurus Labs shares touched a record ₹1,662.45 following a 29% jump in quarterly revenue to ₹2,026 crore. The performance was driven by growth in its CDMO and Affordable Medicines segments. The company has also raised its annual capital spending plan to ₹2,000 crore to meet rising global demand for its manufacturing and fermentation programs.
Detailed Coverage
Laurus Labs shares reached a record intraday peak of ₹1,662.45 on Monday, reflecting a 55% gain over the last five months. This momentum follows a significant period of growth for the pharmaceutical firm, which has seen its share price increase by 176% since May 2025. The rally is supported by the company’s strong financial results for the April-June 2026 quarter.
Financial Growth and Margin Expansion
In its latest earnings report for the first quarter of FY27, Laurus Labs posted a record revenue of ₹2,026 crore, representing a 29% increase compared to the same period last year. Profitability metrics also showed marked improvement, with EBITDA rising 66% to reach ₹644 crore. This growth in earnings was accompanied by an EBITDA margin of 31.8%, supported by higher capacity usage and operational efficiency. The company’s gross margins also expanded by more than 3 percentage points to 62.7%, indicating better cost management and a move toward higher-value products.
Strategic Investments and Future Plans
The company is aggressively expanding its capabilities, recently raising its capital spending guidance for FY27 to ₹2,000 crore, up from the previously planned ₹1,500 crore. This money is directed toward meeting increased customer demand in both human and animal health sectors. Laurus Labs is also focusing on emerging technologies, including Antibody Drug Conjugates (ADCs) and precision fermentation. The company aims to complete the expansion of its fermentation capacity by the end of 2026, which is expected to support the commercialization of new customer programs.
Risks and Market Context
While the company’s recent performance is strong, investors may monitor the risks associated with such high levels of capital spending. Increased debt pressure is a common factor to watch when a company scales up operations rapidly. Additionally, the transition of non-commercial CDMO projects into commercial manufacturing remains a key monitorable, as these projects require ongoing regulatory approvals to generate revenue. The success of these initiatives depends on timely execution and the company's ability to maintain high utilization levels in its newly expanded facilities. Investors should also be aware that the pharmaceutical sector is subject to intense competition and strict regulatory oversight in global markets, which can impact pricing and project timelines.